TNFRSF8 and Hodgkins lymphoma: In 2011, BV was approved for the therapy of relapsed/refractory (R/R) Hodgkin lymphomas and R/R anaplastic large T-cell lymphomas (ALCL), both characterized by aberrant (over)expression of CD30 [31].